Hefei Medicine to Distribute Biohit Products in China | GenomeWeb

NEW YORK (GenomeWeb News) – Finnish biotech firm Biohit today announced a distribution agreement with Hefei Medicine covering China.

The deal covers the distribution and marketing of Biohit's diagnostic products. Financial and other terms of the deal were not disclosed.

Among the products covered by today's announcement are Biohit's GastroPanel blood-based biomarker tests. The tests are for screening and diagnosing Helicobacter pylori.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.

Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.

Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.

British researchers say they've been removed from EU grant applications, according to the Guardian.